BeOne Medicines Ltd. American Depositary Shares — チャート、価格、ニュース (NASDAQ:ONC)

チャート全体を表示

Financials

概要明細書統計

期次年次

Market Capitalization 34.571 B
Employee 12 K
Founded 2010
CEO John Vincent OylerJohn Vincent Oyler
Website www.beonemedicines.com
Headquarter N/A
FIGI BBG00B6WF7T5
Industry Technology

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

34.57 B 時価総額

株価収益率

1 599

売上高対価格比率

83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.